UBT251 for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
Who Is on the Research Team?
Clinical Transparency (dept. 2834)
Principal Investigator
Novo Nordisk A/S
Are You a Good Fit for This Trial?
This trial is for adults with overweight or obesity, defined by specific body mass index (BMI) ranges: 27.0-39.9 kg/m^2 for Part A, 30.0-50.0 kg/m^2 for Part B, and 24-34.9 kg/m^2 for Part C of the study. Participants must be aged between 18 to 65 years depending on the part of the study they are in and have a heritage background as specified (Japanese descent for Japanese participants, Chinese descent for Chinese participants, non-Asian descent otherwise).Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive UBT251 or placebo subcutaneously across multiple dose levels
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- UBT251
Trial Overview
The trial is testing UBT251's safety and effectiveness against obesity compared to a placebo (no active medicine). Participants will randomly receive either UBT251 or placebo without knowing which one they're getting.
How Is the Trial Designed?
11
Treatment groups
Experimental Treatment
Placebo Group
Participants will be randomized to receive dose level 3 subcutaneously.
Participants will be randomized to receive dose level 2 subcutaneously.
Participants will be randomized to receive dose level 1 subcutaneously.
Participants will be randomized to receive a single dose level subcutaneously.
Participants will be randomized to receive 2 dose levels subcutaneously.
Participants will be randomized to receive multiple dose levels subcutaneously.
Participants will be randomized to receive multiple dose levels subcutaneously.
Participants will be randomized to receive multiple dose levels subcutaneously.
Participants will be randomized to receive multiple dose levels subcutaneously.
Participants will receive placebo matched to UBT251 subcutaneously.
Participants will receive placebo matching one of the UBT251 arms subcutaneously.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novo Nordisk A/S
Lead Sponsor
Lars Fruergaard Jørgensen
Novo Nordisk A/S
Chief Executive Officer since 2017
MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark
Martin Holst Lange
Novo Nordisk A/S
Chief Medical Officer since 2021
MD from University of Copenhagen
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.